|
|
|
MIRA INFORM REPORT
|
Report No. : |
507777 |
|
Report Date : |
11.05.2018 |
IDENTIFICATION DETAILS
|
Name : |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
No.6 Weiwu Road, Shangyu Industrial Park, Hangzhou Gulf,
Zhejiang Province |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2016 |
|
|
|
|
Date of Incorporation : |
06.08.2004 |
|
|
|
|
Unified
Social Credit Code.: |
913306007258898636 |
|
|
|
|
Legal Form : |
Limited Liabilities Company (Sino-Foreign Joint Venture) |
|
|
|
|
Line of Business : |
Subject is mainly engaged in R&D, production and sales
of pharmaceutical and veterinary APIs. Its leading products are quinolone
antibacterials, macrolide antibacterials, cephalosporin antibacterials, etc.,
including Ciprofloxacin hydrochloride, enrofloxacin, Azithromycin,
Clarithromycin, roxithromycin, ceftezole sodium, Marbofloxacin, etc. |
|
|
|
|
No. of Employees : |
1,300 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Exist |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state support of key sectors, and a restrictive investment regime. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2016 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.
After keeping its currency tightly linked to the US dollar for years, China in July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing announced it would allow a resumption of gradual liberalization. From 2013 until early 2015, the renminbi (RMB) appreciated roughly 2% against the dollar, but the exchange rate fell 13% from mid-2015 until end-2016 amid strong capital outflows in part stemming from the August 2015 official devaluation; in 2017 the RMB resumed appreciating against the dollar – roughly 7% from end-of-2016 to end-of-2017. From 2013 to 2017, China had one of the fastest growing economies in the world, averaging slightly more than 7% real growth per year. In 2015, the People’s Bank of China announced it would continue to carefully push for full convertibility of the renminbi, after the currency was accepted as part of the IMF’s special drawing rights basket. However, since late 2015 the Chinese Government has strengthened capital controls and oversight of overseas investments to better manage the exchange rate and maintain financial stability.
The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) managing its high corporate debt burden to maintain financial stability; (c) controlling off-balance sheet local government debt used to finance infrastructure stimulus; (d) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (e) dampening speculative investment in the real estate sector without sharply slowing the economy; (f) reducing industrial overcapacity; and (g) raising productivity growth rates through the more efficient allocation of capital and state-support for innovation. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China’s population control policy known as the “one-child policy” - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese Government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.
The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and heavy industry. However, China has made more progress on subsidizing innovation than rebalancing the economy. Beijing has committed to giving the market a more decisive role in allocating resources, but the Chinese Government’s policies continue to favor state-owned enterprises and emphasize stability. Chinese leaders in 2010 pledged to double China’s GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the “dominant” role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time. The slight acceleration in economic growth in 2017—the first such uptick since 2010—gives Beijing more latitude to pursue its economic reforms, focusing on financial sector deleveraging and its Supply-Side Structural Reform agenda, first announced in late 2015.
|
Source
: CIA |
INVESTIGATION
RECORD
|
Name of Interviewee |
A male staff who refused to disclose his name |
|
Tel |
(86 575)82735643 |
|
Investigation Way |
Telephone |
|
|
|
ORDER DETAILS &
INVESTIGATION RESULTS
|
- |
Order Information |
Verification |
|
Name(English) |
ZHEJIANG GUBONG PHARMACEUTICAL CO LTD |
Inaccurate |
|
Address (English) |
NO 6 WEIWU ROAD HANGZHOU GULF SHANGYU 312369 |
Incomplete |
ABSTRACT
|
Name (English) |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. (Confirmed by
Subject's Employee) |
|
Unified Social Credit Code |
913306007258898636 |
|
AIC registration No. |
330600400010566 |
|
National Organization Code |
725889863 |
|
Company Status |
Operational |
|
Executive |
Qiu Jiajun |
|
Registered Capital |
CNY 138,800,000.00 |
|
Date of Establishment |
2004-08-06 |
|
Employee |
1,300 |
|
Website |
www.gbpharm.com |
|
Company Size |
Large |
|
SIC (China) |
2710,Production of Original Medicine of Chemical Drugs |
|
Import/Export Permit |
Yes |
|
Judicial |
17 |
CONTACTS
|
Tel |
(86 575)82735643 |
|
Fax |
(86 575)82730672 |
|
Address |
No.6 Weiwu Road, Shangyu Industrial Park, Hangzhou Gulf,
Shangyu District, Shaoxing City, Zhejiang Province(Factory;
Office) |
|
Address Post code |
312369 |
|
Ownership |
Unknown |
GENERAL
COMMENTS
|
RISK ANALYSIS |
|
Established in Aug. 2004 with registered capital of CNY
138,800,000.00, SC is mainly engaged in R&D, production and sales of
pharmaceutical and veterinary APIs. With years of operation, it has
accumulated rich industry experience. Its shareholders can provide certain
market background and technical support for Subject, which offers convenience
for Subject's development. Currently, with large business scale, stable sales
network and purchasing channels, subject enjoys certain popularity and
influence in the industry. According to Subject’s current financial information, its
operating income of 2016 increases by 4.84% over that of 2015, indicating its
business is developed well in 2016. High net profit margin of 2016 reflects
subject’s profitability is good. Low turnover of total assets of 2016
indicates Subject has poor asset operation capacity. With low liabilities to
assets ratio of 2016, subject has good long-term solvency. |
REGISTRATION
INFORMATION
|
Unified Social Credit Code |
913306007258898636 |
|
AIC registration No. |
330600400010566 |
|
Date of Establishment |
2004-08-06 |
|
Registered Address |
No.6 Weiwu Road, Shangyu Industrial Park, Hangzhou Gulf,
Zhejiang Province |
|
Registry |
Market Supervision Administration - Shaoxing City |
|
Legal Representative |
Qiu Jiajun |
|
Legal Form |
Limited Liabilities Company (Sino-Foreign Joint Venture) |
|
Registered Capital |
CNY 138,800,000.00 |
|
Paid-in Capital |
CNY 138,800,000.00 |
|
Latest Year of Annual Report |
2016 |
|
Operation duration |
2004-08-06 to 2024-08-05 |
|
Business Scope |
Production of veterinary powder / premix, oral solution,
non-aseptic APIs (Ciprofloxacin hydrochloride, enrofloxacin, diclazuril,
Cyclopromethazine, Danofloxacin Mesylate, Marbofloxacin, Enrofloxacin
hydrochloride, norfloxacin, Toltrazuril, Gamithromycin and tulathromycin),
APIs (Deoxyuridine, Ciprofloxacin hydrochloride, Azithromycin, roxithromycin,
Clarithromycin, norfloxacin, ciprofloxacin lactate, Simvastatin,
Levamlodipine Besylate, fudosteine, azelnidipine, mitiglinide calcium,
cefixime, cefuroxime axetil, Moxifloxacin hydrochloride, Levofloxacin,
Levofloxacin Hydrochloride, solifenacin succinate, solifenacin succinate,
Azilsartan, rivaroxaban and Apixaban); Production of ethanol, methanol, hydrochloric acid,
dichloromethane, toluene, acetonitrile, ethyl acetate, isopropanol,
cyclohexane, acetone, isoamyl alcohol, xylene, piperazine, Dimethylformamide,
formic acid, diazabicyclo, dioxane, triethylamine, acetic acid, propionic
acid, mercapto acetic acid, methyl acetate, butyl acetate; Production of mercapto benzothiazole, ammonium chloride,
imidazole, sodium chloride, sodium sulfite, potassium bromide, sodium
sulphate, paroline, ammonium sulphate, Cyclopropane carboxylic acid,
Dihydrohigh erythromycin., Erythromycin oxime, sodium iso-octoate, Valerate,
alumina, iodine, triphenylphosphine oxide, dimethylamine hydrochloride,
Benzothiazole, potassium chloride; Sales of self-produced products; (Of the above business projects where a permit is
required, permit shall be obtained.) |
REGISTRATION
CHANGES
|
- |
Date |
Item Changed |
From |
To |
|
1 |
2012-04-18 |
Shareholder |
Antou Holdings Limited (CNY 33,312,000.00), GUOBANG PHARMACHEM
GROUP CO., LTD. (CNY 55,520,000.00) and Yubang Investment Ltd (CNY 49,968,000.00) |
Antou Holdings Limited CNY 55,628,264.00), GUOBANG
PHARMACHEM GROUP CO., LTD. (CNY 55,520,000.00) and Yubang Investment Lt) (CNY
27,651,736.00) |
|
2 |
2011-06-29 |
Shareholder |
GUOBANG PHARMACHEM GROUP CO., LTD. (CNY 55,520,000.00) and
Yubang Investment Ltd (CNY
83,280,000.00) |
Antou Holdings Limited ((CNY 33,312,000.00), GUOBANG
PHARMACHEM GROUP CO., LTD.(CNY 55,520,000.00) and Yubang Investment Ltd (CNY
49,968,000.00) |
|
3 |
2010-12-13 |
Registered
capital |
CNY80,800,000.00 |
CNY138,800,000.00 |
|
4 |
2010-12-13 |
Shareholder |
GUOBANG PHARMACHEM GROUP CO., LTD (CNY 32,320,000.00) and
Yubang Investment Ltd (CNY 48,480,000.00) |
GUOBANG PHARMACHEM GROUP CO., LTD. (CNY 55,520,000.00) and
Yubang Investment Ltd (CNY 83,280,000.00) |
|
5 |
2009-05-08 |
Registered
Address |
Weiwu Road, Shangyu Fine Chemical Park |
No.6 Weiwu Road, Shangyu Industrial Park, Hangzhou Gulf, Zhejiang
Province |
|
6 |
2009-05-08 |
Shareholder |
Yubang Investment Ltd (CNY 80,800,000.00) |
GUOBANG PHARMACHEM GROUP CO., LTD. (CNY 32,320,000.00) and Yubang Investment
Ltd ) (CNY 48,480,000.00) |
|
7 |
2005-12-23 |
Registered
capital |
CNY32,000,000.00 |
CNY80,800,000.00 |
|
8 |
2005-12-23 |
Shareholder |
Yubang Investment Ltd
(CNY 32,000,000.00) |
Yubang Investment Ltd (CNY 80,800,000.00) |
|
9 |
2005-09-14 |
Name |
ZHEJIANG GUOBANG VETERINARY DRUGS CO., LTD. ) |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
10 |
2004-12-17 |
Legal
representative |
Zhang Qiong |
Qiu Jiajun |
|
11 |
2004-10-26 |
Shareholder |
Yubang Investment Ltd
(CNY 20,000,000.00) |
Yubang Investment Ltd
(CNY 32,000,000.00) |
|
12 |
2004-10-26 |
Registered
capital |
CNY20,000,000.00 |
CNY32,000,000.00 |
SHAREHOLDER
INFORMATION
|
- |
Name |
% Ownership |
Capital Contributed |
Currency |
Investment Way |
Paid-in % |
Country |
|
1 |
Antou Holdings Limited |
40.08 |
55,628,264.00 |
CNY |
Capital |
100 |
BVI |
|
2 |
GUOBANG PHARMACHEM GROUP CO.,
LTD. |
40.00 |
55,520,000.00 |
CNY |
Capital |
100 |
China |
|
3 |
Yubang Investment Ltd |
19.92 |
27,651,736.00 |
CNY |
Capital |
100 |
BVI |
|
Total |
|
100.0 |
138,800,000 |
|
|
|
|
ENTITY SHAREHOLDER
|
Name (English) |
Antou Holdings Limited |
|
Country |
BVI |
|
Name (English) |
GUOBANG PHARMACHEM GROUP CO., LTD. |
|
Country |
China |
|
Legal Representative |
Qiu Jiajun |
|
Registration No. |
330600400009418 |
|
Unified Social Credit Code |
91330600609690857C |
|
Date of Establishment |
1996-03-29 |
|
Legal Form |
Limited Liabilities Company (Sino-Foreign Joint Venture) |
|
Registered Capital |
USD 9,295,900.00 |
|
Status |
Operational |
|
Registered Address |
No.60 Xingmei Ave, Xinchang Provincial High-tech
Industrial Park |
|
Name (English) |
Yubang Investment Ltd |
|
Country |
BVI |
ULTIMATE
HOLDING
|
- |
Ultimate Shareholder |
Investment Way |
|
1 |
Antou Holdings Limited |
Capital |
|
English Name |
Antou Holdings Limited |
|
Country |
BVI |
|
Type |
Entity Shareholder |
|
Investment Way |
Capital |
|
Note |
Antou Holdings Limited -->40.08% ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
No branch information of subject is searched out from
database.
INVESTMENT
IN OTHER COMPANIES
|
- |
Name |
License Status |
Share Holding |
Currency |
% Ownership |
|
1 |
Shaoxing
Chenyu Chemical Co., Ltd. |
Operational |
25,000,000.00 |
CNY |
100 |
|
2 |
Shaoxing
Fujian Environmental Protection Technology Co., Ltd. |
Operational |
5,000,000.00 |
CNY |
100.00 |
|
3 |
Shaoxing
Shangyu Lianxin Recycled Material Recovery Co., Ltd |
Operational |
275,000.00 |
CNY |
55.00 |
|
4 |
ZHEJIANG
DONGYING PHARMACEUTICAL CO.,LTD. |
Operational |
234,057,776.00 |
CNY |
100.00 |
|
5 |
Zhejiang
Huada Pharmaceutical R & D Co., Ltd |
Operational |
52,880,000.00 |
CNY |
100.00 |
|
Name (English) |
Shaoxing Chenyu Chemical Co., Ltd. |
|
Unified Social Credit Code |
913306043255326623 |
|
License Status |
Operational |
|
Registration No. |
330682000171230 |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Legal Form |
Limited Liabilities Company |
|
Country |
China |
|
Registered Capital |
CNY 25,000,000.00 |
|
Type |
Subsidiary |
|
Date of Establishment |
2014-12-11 |
|
Share Holding |
25,000,000.00 |
|
Currency |
CNY |
|
% Ownership |
100 |
|
Name (English) |
Shaoxing Fujian Environmental Protection Technology Co.,
Ltd. |
|
Unified Social Credit Code |
91330604MA28843CX3 |
|
License Status |
Operational |
|
Registration No. |
330682000194291 |
|
Name Of Legal Representative |
Yao Ligao |
|
Legal Form |
Limited Liabilities Company |
|
Country |
China |
|
Registered Capital |
CNY 5,000,000.00 |
|
Type |
Subsidiary |
|
Date of Establishment |
2015-12-14 |
|
Share Holding |
5,000,000.00 |
|
Currency |
CNY |
|
Way of Investment |
Capital |
|
% Ownership |
100.00 |
|
Name (English) |
Shaoxing Shangyu Lianxin Recycled Material Recovery Co.,
Ltd |
|
Unified Social Credit Code |
9133060469385899XH |
|
License Status |
Operational |
|
Registration No. |
330682000054740 |
|
Name Of Legal Representative |
Lian Qiquan |
|
Legal Form |
Limited Liabilities Company |
|
Country |
China |
|
Registered Capital |
CNY 500,000.00 |
|
Type |
Subsidiary |
|
Date of Establishment |
2009-09-04 |
|
Share Holding |
275,000.00 |
|
Currency |
CNY |
|
Way of Investment |
Capital |
|
% Ownership |
55.00 |
|
Name (English) |
ZHEJIANG DONGYING PHARMACEUTICAL CO.,LTD. |
|
Unified Social Credit Code |
913306047804696423 |
|
License Status |
Operational |
|
Registration No. |
330600400014325 |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Legal Form |
Limited Liabilities Company |
|
Country |
China |
|
Registered Capital |
CNY 234,057,776.00 |
|
Type |
Subsidiary |
|
Date of Establishment |
2005-10-19 |
|
Share Holding |
234,057,776.00 |
|
Currency |
CNY |
|
Way of Investment |
Capital |
|
% Ownership |
100.00 |
|
Name (English) |
Zhejiang Huada Pharmaceutical R & D Co., Ltd |
|
Unified Social Credit Code |
91330604739927162M |
|
License Status |
Operational |
|
Registration No. |
330682000010562 |
|
Name Of Legal Representative |
Meng Zhongjian |
|
Legal Form |
Limited Liabilities Company |
|
Country |
China |
|
Registered Capital |
CNY 52,880,000.00 |
|
Type |
Subsidiary |
|
Date of Establishment |
2002-06-05 |
|
Share Holding |
52,880,000.00 |
|
Currency |
CNY |
|
Way of Investment |
Capital |
|
% Ownership |
100.00 |
MANAGEMENT
|
Name |
Qiu Jiajun |
|
Country |
China |
|
Position |
Chairman; General Manager |
|
Gender |
Male |
|
Age |
54 |
INVOLVEMENT IN OTHER COMPANIES
|
- |
Name (English) |
License Status |
Legal Representative |
Position |
Type of Engagement |
|
1 |
GUOBANG
PHARMACHEM GROUP CO., LTD. |
Operational |
YES |
Chairman;
General Manager |
Directorship |
|
2 |
Hangzhou
Guobang Enterprise Management Co., Ltd. |
Operational |
YES |
Chairman |
Directorship |
|
3 |
Hangzhou
Guoyi Industrial Co., Ltd. |
Operational |
YES |
Chairman |
Directorship |
|
4 |
Hangzhou
Yaoda Economic Information Consulting Co., Ltd. |
Operational |
YES |
Executive
Director |
Directorship;
Investment(10.00%) |
|
5 |
SHANDONG
GUOBANG PHARMACEUTICAL CO., LTD. |
Operational |
NO |
Director |
Directorship;
Investment(12.74%) |
|
6 |
Shaoxing
Chenyu Chemical Co., Ltd. |
Operational |
YES |
Executive
Director |
Directorship |
|
7 |
Shaoxing
Shangyu Gongsheng Trade Co., Ltd |
Operational |
YES |
Executive
Director; General Manager |
Directorship |
|
8 |
Xinchang
Ande Trading Co., Ltd |
Operational |
YES |
Executive
Director; General Manager |
Directorship;
Investment(54.55%) |
|
9 |
Xinchang
Ansheng Investment Co., Ltd |
Operational |
YES |
Executive
Director |
Directorship;
Investment(60.00%) |
|
10 |
Xinchang
Hebao Biotechnology Co., Ltd. |
Operational |
YES |
Executive
Director; General Manager |
Directorship |
|
11 |
ZHEJIANG
DONGYING PHARMACEUTICAL CO.,LTD. |
Operational |
YES |
Chairman;
General Manager |
Directorship |
|
12 |
Quzhou
Guobang Health Industry Management Co., Ltd. |
Operational |
YES |
Chairman |
Directorship;
Investment(20.00%) |
|
13 |
Quzhou
Guoyi Shanju Health Industry Co., Ltd. |
Operational |
YES |
Chairman |
Directorship |
|
Name (English) |
GUOBANG PHARMACHEM GROUP CO., LTD. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
USD 9,295,900.00 |
|
Country |
China |
|
Registration No. |
330600400009418 |
|
Unified Social Credit Code |
91330600609690857C |
|
Legal Form |
Limited Liabilities Company (Sino-Foreign Joint Venture) |
|
Position |
Chairman; General Manager |
|
Date of Establishment |
1996-03-29 |
|
Name (English) |
Hangzhou Guobang Enterprise Management Co., Ltd. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 5,000,000.00 |
|
Country |
China |
|
Registration No. |
330108000099397 |
|
Unified Social Credit Code |
91330108596628965Y |
|
Legal Form |
Limited Liabilities Company |
|
Position |
Chairman |
|
Date of Establishment |
2012-05-31 |
|
Name (English) |
Hangzhou Guoyi Industrial Co., Ltd. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 100,000,000.00 |
|
Country |
China |
|
Registration No. |
330181000529236 |
|
Unified Social Credit Code |
91330109352424739H |
|
Legal Form |
Limited Liabilities Company |
|
Position |
Chairman |
|
Date of Establishment |
2015-08-17 |
|
Name (English) |
Hangzhou Yaoda Economic Information Consulting Co., Ltd. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 100,000.00 |
|
Country |
China |
|
Registration No. |
330108000099143 |
|
Unified Social Credit Code |
913301085966289574 |
|
Legal Form |
Limited Liabilities Company |
|
Share Holding |
10,000.00 |
|
Currency Of Share Holding |
CNY |
|
Way of Investment |
Capital |
|
% Ownership |
10.00 |
|
Position |
Executive Director |
|
Date of Establishment |
2012-06-01 |
|
Name (English) |
SHANDONG GUOBANG PHARMACEUTICAL CO., LTD. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Zhu Yaqing |
|
Registered Capital |
CNY 104,730,000.00 |
|
Country |
China |
|
Registration No. |
370700228073580 |
|
Unified Social Credit Code |
91370700796196618F |
|
Legal Form |
Shares Limited Company (Unlisted) |
|
Share Holding |
13,340,000.00 |
|
Currency Of Share Holding |
CNY |
|
Way of Investment |
Capital |
|
% Ownership |
12.74 |
|
Position |
Director |
|
Date of Establishment |
2006-12-13 |
|
Name (English) |
Shaoxing Chenyu Chemical Co., Ltd. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 25,000,000.00 |
|
Country |
China |
|
Registration No. |
330682000171230 |
|
Unified Social Credit Code |
913306043255326623 |
|
Legal Form |
Limited Liabilities Company |
|
Position |
Executive Director |
|
Date of Establishment |
2014-12-11 |
|
Name (English) |
Shaoxing Shangyu Gongsheng Trade Co., Ltd |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
HKD 77,080,000.00 |
|
Country |
China |
|
Registration No. |
330600400023473 |
|
Unified Social Credit Code |
91330600598527017M |
|
Legal Form |
Limited Liabilities Company (Foreign Invested) |
|
Position |
Executive Director; General Manager |
|
Date of Establishment |
2012-06-26 |
|
Name (English) |
Xinchang Ande Trading Co., Ltd |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 500,000.00 |
|
Country |
China |
|
Registration No. |
330624000030146 |
|
Unified Social Credit Code |
913306245586385565 |
|
Legal Form |
Limited Liabilities Company |
|
Share Holding |
272,750.00 |
|
Currency Of Share Holding |
CNY |
|
Way of Investment |
Capital |
|
% Ownership |
54.55 |
|
Position |
Executive Director; General Manager |
|
Date of Establishment |
2010-07-16 |
|
Name (English) |
Xinchang Ansheng Investment Co., Ltd |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 10,000,000.00 |
|
Country |
China |
|
Registration No. |
330624000081970 |
|
Unified Social Credit Code |
91330624MA28814C81 |
|
Legal Form |
Limited Liabilities Company |
|
Share Holding |
6,000,000.00 |
|
Currency Of Share Holding |
CNY |
|
% Ownership |
60.00 |
|
Position |
Executive Director |
|
Date of Establishment |
2015-10-23 |
|
Name (English) |
Xinchang Hebao Biotechnology Co., Ltd. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 20,000,000.00 |
|
Country |
China |
|
Registration No. |
330624000007648 |
|
Unified Social Credit Code |
913306247045057603 |
|
Legal Form |
Limited Liabilities Company |
|
Position |
Executive Director; General Manager |
|
Date of Establishment |
1999-03-26 |
|
Name (English) |
ZHEJIANG DONGYING PHARMACEUTICAL CO.,LTD. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 234,057,776.00 |
|
Country |
China |
|
Registration No. |
330600400014325 |
|
Unified Social Credit Code |
913306047804696423 |
|
Legal Form |
Limited Liabilities Company |
|
Position |
Chairman; General Manager |
|
Date of Establishment |
2005-10-19 |
|
Name (English) |
Quzhou Guobang Health Industry Management Co., Ltd. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 100,000,000.00 |
|
Country |
China |
|
Registration No. |
330822000052381 |
|
Legal Form |
Limited Liabilities Company |
|
Share Holding |
20,000,000.00 |
|
Currency Of Share Holding |
CNY |
|
% Ownership |
20.00 |
|
Position |
Chairman |
|
Date of Establishment |
2017-08-01 |
|
Name (English) |
Quzhou Guoyi Shanju Health Industry Co., Ltd. |
|
License Status |
Operational |
|
Name Of Legal Representative |
Qiu Jiajun |
|
Registered Capital |
CNY 100,000,000.00 |
|
Country |
China |
|
Registration No. |
330822000011828 |
|
Unified Social Credit Code |
913308226995317601 |
|
Legal Form |
Limited Liabilities Company |
|
Position |
Chairman |
|
Date of Establishment |
2010-01-11 |
MANAGEMENT
|
- |
Name |
Position |
Gender |
|
1 |
Qiu Jiajun |
Chairman; General Manager |
Male |
DIRECTORS AND SUPERVISORS
|
- |
Name |
Position |
Gender |
|
1 |
Qiu Jiajun |
Chairman;
General Manager |
Male |
|
2 |
Mao Shifu |
Director |
- |
|
3 |
Zhu Yaqing |
Director |
- |
|
4 |
Zhu Mingxing |
Director |
- |
|
5 |
Gong
Yuda |
Director |
- |
|
6 |
Gao Yuntai |
Supervisor |
- |
JUDICIAL
INFORMATION
As of the reporting date, no related record about subject is
found through below sources:
A. Website of China Court Organization;
B. Websites of local courts of subject's location;
C. Websites of major domestic courts;
SUBJECT
AS EXECUTED PARTY
As of the reporting date, no related record about subject is
found through below sources:
A. Website of China Court Organization;
B. Websites of local courts of subject's location;
C. Websites of major domestic courts;
CIVIL & COMMERCIAL TRIAL PROCESS
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0604 Min Chu 7644 |
|
Position |
Plaintiff |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Date Type |
Filing Date |
|
Date |
2016-11-11 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0604 Min Chu 5992 |
|
Position |
Defendant |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Date Type |
Trial Date |
|
Date |
2016-10-09 |
|
Cause |
Labor dispute |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0604 Min Chu 3677 |
|
Position |
Plaintiff |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Date Type |
Filing Date |
|
Date |
2016-05-17 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0604 Min Chu 3671 |
|
Position |
Plaintiff |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Date Type |
Filing Date |
|
Date |
2016-05-17 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0604 Min Chu 2312 |
|
Position |
Party Involved |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Date Type |
Delivery Date |
|
Date |
2016-05-14 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0103 Min Chu 2914 |
|
Position |
Plaintiff |
|
Hearing Court |
People’s Court of Xiacheng Dist, Hangzhou City, Zhejiang
Province |
|
Date Type |
Filing Date |
|
Date |
2016-04-28 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2014) SHAO Yu Xing Chu Zi 76 |
|
Position |
Party Involved |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Date Type |
Filing Date |
|
Date |
2014-01-08 |
CIVIL
& COMMERCIAL JUDGMENT DOCUMENT
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2017) ZHE 0604 Zhi Yi 24 |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Court Type |
Basic People’s Court |
|
Cause of Action |
Opposition to execution |
|
Value |
0 |
|
Position |
Appellor |
|
Date of Closing |
2017-07-26 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2017) ZHE 0604 Zhi 307 |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Court Type |
Basic People’s Court |
|
Cause of Action |
Dispute of pledge contract |
|
Value |
0 |
|
Position |
Appellor |
|
Date of Closing |
2017-03-03 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2017) ZHE 0604 Zhi 306 |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Court Type |
Basic People’s Court |
|
Cause of Action |
Dispute of pledge contract |
|
Value |
0 |
|
Position |
Appellor |
|
Date of Closing |
2017-03-03 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0604 Min Chu 7644 |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Court Type |
Basic People’s Court |
|
Cause of Action |
Dispute of recourse |
|
Value |
60,895,580.85 |
|
Position |
Plaintiff |
|
Date of Closing |
2016-12-22 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0604 Min Chu 2312 |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Court Type |
Basic People’s Court |
|
Cause of Action |
Motor vehicle traffic accident liability dispute |
|
Value |
133,300 |
|
Position |
Plaintiff |
|
Date of Closing |
2016-08-12 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0604 Min Chu 3671 |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Court Type |
Basic People’s Court |
|
Cause of Action |
Dispute of pledge contract |
|
Value |
0 |
|
Position |
Plaintiff |
|
Date of Closing |
2016-08-10 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2016) ZHE 0604 Min Chu 3677 |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City, Zhejiang
Province |
|
Court Type |
Basic People’s Court |
|
Cause of Action |
Dispute of pledge contract |
|
Value |
0 |
|
Position |
Plaintiff |
|
Date of Closing |
2016-08-10 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Government ID. / AIC Registration No. |
913306007258898636 |
|
File No. |
(2012) SHAO Zhu Mei Shang Chu Zi 159 |
|
Hearing Court |
People’s Court of Zhuji City, Zhejiang Province |
|
Court Type |
Basic People’s Court |
|
Cause of Action |
Sales contract dispute |
|
Value |
0 |
|
Position |
Defendant |
|
Date of Closing |
2012-04-19 |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
File No. |
(2010) ZHE Shao Min Zhong Zi 105 |
|
Hearing Court |
Intermediate People’s Court of Shaoxing City, Zhejiang
Province |
|
Court Type |
Intermediate People’s Court |
|
Cause of Action |
Unjust enrichment dispute |
|
Position |
Defendant |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
File No. |
(2014) SHAO Yu Xing Chu Zi 76 |
|
Hearing Court |
People’s Court of Shangyu Dist, Shaoxing City |
|
Court Type |
Basic People’s Court |
|
Cause of Action |
Larceny |
ADMINISTRATIVE ILLEGAL RECORDS
As of the reporting date, no related record about subject is
found through below sources:
A. Website of China Court Organization;
B. Websites of local courts of subject's location;
C. Websites of major domestic courts;
OPERATION
INFORMATION
|
Main Business |
R&D, production and sales of pharmaceutical and
veterinary APIs |
|
Products & Service |
SC is mainly engaged in R&D, production and sales of
pharmaceutical and veterinary APIs. Its leading products are quinolone
antibacterials, macrolide antibacterials, cephalosporin antibacterials, etc.,
including Ciprofloxacin hydrochloride, enrofloxacin, Azithromycin,
Clarithromycin, roxithromycin, ceftezole sodium, Marbofloxacin, etc. |
|
Production Information |
Subject has state-level postdoctoral research station,
provincial drug research institute and provincial enterprise technology
center. |
|
OTHER INFORMATION |
Subject has obtained ISO 9001: 2008, ISO14001, GMP, EUGMP
(EU), FDA (USA), PMDA (Japan), ANVISA (Brazil), KFDA (South Korea), etc. The information of Subject's Production Licence for
Medicines obtained from official source is as below: Company Name: ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD.; Registered Address: No.6 Weiwu Road, Shangyu Industrial
Park, Hangzhou Gulf, Zhejiang Province; Legal Representative: Qiu Jiajun Person in Charge: Yao Ligao Quality Supervisor: Zhou Likui ; Legal Form: Limited Liabilities Company (Sino-Foreign
Joint Venture); Licence No.: ZHE 20050288; Scope of Production: APIs; Date of Issuance: 2016-01-06; Date of Expiry: 2019-12-24. |
OPERATION
FACILITIES
|
Business Address |
No.6 Weiwu Road, Shangyu Industrial Park, Hangzhou Gulf,
Shangyu District, Shaoxing City, Zhejiang Province(Factory;
Office) |
|
Tel |
(86 575)82735643 |
|
Fax |
(86 575)82730672 |
|
Post code |
312369 |
|
Environment |
Major industrial areas |
|
Ownership |
Unknown |
|
Traffic Condition |
Convenient |
|
Region |
Products |
Customer Type |
Number of Customers |
Payment Terms |
Region |
Percentage |
|
|
Domestic |
Pharmaceutical and veterinary APIs, etc |
Medical institutions, traders, etc |
Over 50 |
Credit payment, immediate
payment, etc |
All over China |
45 |
|
|
International |
Pharmaceutical and veterinary
APIs, etc |
Traders, etc |
Over 50 |
L/C, T/T, etc |
Europe, America, Asia, etc. |
55 |
|
|
OTHER INFORMATION |
SC's sales business is developed at home and abroad. Its
domestic sales network covers all over China and its exporting regions cover
Bangladesh, India, the Netherlands, Spain, Germany, Vietnam, South Korea,
etc. Its customers include medical institutions, traders, etc. Currently it
has established certain sales network. |
||||||
MAJOR CUSTOMERS
|
- |
Name |
Legal Form |
Country |
|
1 |
JIANGSU SHENLONG
PHARMACEUTICAL CO., LTD. |
Shares Limited Company
(Unlisted) |
China |
|
Name (English) |
JIANGSU SHENLONG PHARMACEUTICAL CO., LTD. |
|
Country |
China |
|
Legal Form |
Shares Limited Company (Unlisted) |
|
Region |
Main Products Purchased |
Number of Suppliers |
Payment Terms |
Region |
Percentage |
|
|
Domestic |
Hydroxylamine hydrochloride
and other chemical raw materials, production equipment, office supplies, etc |
Over 20 |
Credit payment, immediate
payment, etc |
All over China |
80 |
|
|
International |
Plastic bags, etc |
Over 5 |
L/C, T/T, etc |
Pakistan, Turkey, the United States, etc. |
20 |
|
|
OTHER INFORMATION |
SC's purchasing business is developed at home and abroad.
Its hydroxylamine hydrochloride and other chemical raw materials, production
equipment, office supplies, etc are mainly purchased domestically and partial
plastic bags, etc are imported from Pakistan, Turkey, the United States, etc.
Currently it has stable purchasing channels. |
|||||
MAJOR SUPPLIERS
|
- |
Name |
Legal Form |
Country |
|
1 |
SHANDONG BAOYUAN CHEMICAL CO.,LTD. |
Limited Liabilities Company |
China |
|
Name (English) |
SHANDONG BAOYUAN CHEMICAL CO.,LTD. |
|
Country |
China |
|
Legal Form |
Limited Liabilities Company |
|
- |
Supplier Name |
Product Supplied |
Cooperation Period |
Payment History |
|
1 |
SHANDONG BAOYUAN CHEMICAL
CO.,LTD. |
Hydroxylamine hydrochloride,
etc |
Long term |
Prompt |
|
Name (English) |
SHANDONG BAOYUAN CHEMICAL CO.,LTD. |
|
Country |
China |
|
Product Supplied |
Hydroxylamine hydrochloride, etc |
|
Payment History |
Prompt |
|
Cooperation Period |
Long term |
|
Terms |
Prepayment |
|
Date of Interview |
2018-05-08 |
|
Name of Interviewee |
A male staff who refused to disclose his name |
|
Tel |
(86 533) 8516388 |
|
Comment |
The referee confirmed that Subject is one of the above
company’s clients and Subject made payment in time. |
|
- |
File No. |
Mortgagee Name |
Mortgagee Type |
Mortgagor Name |
Collateral |
|
1 |
Yu
Gong Shang Zi 276249 |
Bank
of Communications Limited Shaoxing Xinchang Branch |
- |
ZHEJIANG
GUOBANG PHARMACEUTICAL CO., LTD. |
Real
estate (including land area of 85,770 square meters) |
|
File No. |
Yu Gong Shang Zi 276249 |
|
Mortgagee Name |
Bank of Communications Limited Shaoxing Xinchang Branch |
|
Mortgage Type |
Chattel mortgage |
|
Mortgagor Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Collateral |
Real estate (including land area of 85,770 square meters) |
|
Quantity, quality, condition, location, etc |
7,427 |
|
Type of Principal Debt |
Loans |
|
Principal Claim Amount |
CNY 66,000,000 |
|
Start Date |
2012-12-19 |
|
End Date |
2014-12-18 |
|
File Party |
Administration Bureau of Industry and Commerce - Shangyu
City |
ELECTRICITY CONSUMPTION RECORD
No electricity consumption record of subject can be obtained
as the electricity consumer may not be filed with subject's name.
QUALIFICATIONS &
TRENDS
|
- |
Patent Name |
Patent Type |
Status |
Application No. |
Application date |
Classification |
Publication No. |
|
1 |
Synthesis of floxacin |
Invention |
Published |
CN201710826618.7 |
2017-09-14 |
C07D498/06(2006.01)I |
CN107522718A |
|
2 |
Reduction method of phenylacetonitrile |
Invention |
Published |
CN201710199266.7 |
2017-03-29 |
C07C253/30(2006.01)I; C07C253/34(2006.01)I;
C07C255/42(2006.01)I |
CN106883148A |
|
3 |
Flocculating sedimentation device |
Patent for utility models |
Approved |
CN201720019623.2 |
2017-01-09 |
C02F1/52(2006.01)I; C02F9/04(2006.01)I |
CN206486330U |
|
4 |
Circulating water filtration concentration device |
Patent for utility models |
Approved |
CN201720019946.1 |
2017-01-09 |
C02F9/04(2006.01)I; C02F11/12(2006.01)I |
CN206486377U |
|
5 |
Crystal reaction equipment for Roxithromycin production |
Patent for utility models |
Approved |
CN201720019878.9 |
2017-01-09 |
B01D9/02(2006.01)I; B01J19/18(2006.01)I;
B01J4/02(2006.01)I; B01J19/00(2006.01)I |
CN206483181U |
|
6 |
Centrifuge structure |
Patent for utility models |
Approved |
CN201720019876.X |
2017-01-09 |
B04B7/06(2006.01)I |
CN206483583U |
|
7 |
Preparation method of Gamithromycin |
Invention |
Published |
CN201610087766.7 |
2016-02-17 |
C07H17/00(2006.01)I; C07H1/00(2006.01)I |
CN105646618A |
|
8 |
Clarithromycin crystal transformation method |
Invention authorization |
Published |
CN201310046349.4 |
2013-02-06 |
C07H17/08(2006.01)I; C07H1/06(2006.01)I |
CN103087130B |
|
9 |
Preparation method of azithromycin |
Invention authorization |
Published |
CN201310046347.5 |
2013-02-06 |
C07H17/00(2006.01)I; C07H1/00(2006.01)I |
CN103087125B |
|
10 |
Preparation method of Levofloxacin |
Invention |
Published |
CN201310040233.X |
2013-02-01 |
C07D498/06(2006.01)I |
CN103113388A |
|
11 |
Synthesis method of fudosteine |
Invention |
Published |
CN201310040183.5 |
2013-02-01 |
C07C323/58(2006.01)I; C07C319/18(2006.01)I |
CN103113273A |
|
12 |
Preparation of 1- methyl -5-[3- methyl -4- (4-
trifluoromethane-phenoxy) - phenyl]-biuret and application thereof |
Invention authorization |
Published |
CN201210214999.0 |
2012-06-27 |
C07C323/20(2006.01)I; C07C319/20(2006.01)I;
C07D251/30(2006.01)I |
CN102731351B |
|
13 |
Methylation in clarithromycin synthesis process and
recovery method of methylation reagents |
Invention authorization |
Published |
CN201210214998.6 |
2012-06-27 |
C07H17/08(2006.01)I |
CN102718821B |
|
14 |
Synthesis method of Clarithromycin intermediate |
Invention authorization |
Published |
CN201210068990.3 |
2012-03-15 |
C07H23/00(2006.01)I; C07H1/00(2006.01)I |
CN102633851B |
|
15 |
Crystallization method of G - G trihydrate |
Invention |
Published |
CN201110429323.9 |
2011-12-20 |
C07D501/22(2006.01)I; C07D501/12(2006.01)I;
C07D501/04(2006.01)I |
CN102516262A |
|
16 |
Preparation method of Azithromycin-hydrate |
Invention authorization |
Published |
CN201110429250.3 |
2011-12-20 |
C07H17/00(2006.01)I; C07H1/00(2006.01)I |
CN102417531B |
|
17 |
A kind of cooling system |
Patent for utility models |
Approved |
CN201120536322.X |
2011-12-20 |
F04D29/58(2006.01)I |
CN202402362U |
|
18 |
Preparation method of (R,S) 1-Bromo ethyl acetate |
Invention authorization |
Published |
CN201110429303.1 |
2011-12-20 |
C07C69/63(2006.01)I; C07C67/287(2006.01)I |
CN102417451B |
|
19 |
Synthetic method of 5- deamine-6-o-methylerythromycin. |
Invention |
Published |
CN201110429285.7 |
2011-12-20 |
C07H17/08(2006.01)I; C07H1/00(2006.01)I |
CN102417532A |
|
20 |
Preparation method of Cefdinir |
Invention |
Published |
CN201110429321.X |
2011-12-20 |
C07D501/22(2006.01)I; C07D501/04(2006.01)I; C07D501/12(2006.01)I |
CN102516261A |
AUTHENTICATION
INFORMATION
|
- |
Certificate Category |
Certificate No. |
Issue Date |
Expire Date |
Status |
|
1 |
Environmental Management System Certification |
05616E20104R3L |
2016-12-30 |
2018-09-15 |
Valid |
|
2 |
Quality Management System Certification (ISO9000) |
15/15Q6879R50 |
2015-12-09 |
2018-09-14 |
Valid |
|
3 |
Environmental Management System Certification |
05614E20012R2M |
2014-01-24 |
2017-01-23 |
Expired |
|
4 |
Quality Management System Certification (ISO9000) |
15/12Q6548R40 |
2012-11-30 |
2015-11-29 |
Expired |
EXPORT/IMPORT
PERMIT
|
EXPORT/IMPORT PERMIT |
Yes |
|
2016 Import / Export Volume (USD 1,000) |
|
|
Import Volume |
Export Volume |
|
3.00 |
123,475.00 |
|
|
||||||||
|
|
||||||||||||||||
|
|
||||||||
|
|
||||||||||||||
|
2015 Import / Export Volume (USD 1,000) |
|
|
Import Volume |
Export Volume |
|
9.00 |
129,946.00 |
|
|
||||||||
|
|
||||||||||||||||
|
|
||||||||
|
|
||||||||||||||
|
Employee Number |
1,300 |
|
OTHER INFORMATION |
The above information was obtained from public channels. |
WEBSITES
|
- |
Website |
Name |
File No |
Registrant |
|
1 |
ZHEJIANG
GUOBANG PHARMACEUTICAL CO., LTD |
|
Website |
|
|
Country |
China |
|
Status |
Normal |
|
Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD |
|
Sponsor Name |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. |
|
Hosted By |
Company |
|
File No. |
Zhe ICP 08011652-1 |
|
Registrant |
Xu Xuejun |
|
Source |
Ministry of Industry and Information Technology |
ADMINISTRATIVE
INFORMATION
ADMINISTRATIVE LICENSES &
IDENTIFICATIONS
|
- |
License No. |
License Name |
|
1 |
ZJ20150093 |
Good Supply Practice Certification |
|
2 |
AQB330682WHⅢ20170170 |
Standard enterprise for safety production |
|
3 |
ZJ20150167 |
Good Supply Practice Certification |
|
4 |
ZJ20130125 |
Good Supply Practice Certification |
|
5 |
(ZJ)WH AN XU ZHENG ZI (2015)-D-2260 |
Administrative license for safety production |
|
6 |
(ZJ)WH AN XU ZHENG ZI
(2017)-D-0305 |
Administrative license for safety production |
|
License No. |
ZJ20150093 |
|
License Name |
Good Supply Practice Certification |
|
Expire date |
2020-07-06 |
|
Issuing party |
Zhejiang Food and Drug Administration |
|
License Content |
APIs (Ciprofloxacin lactate, mitiglinide calcium,
azelnidipine and Doxifluridine) |
|
License No. |
AQB330682WHⅢ20170170 |
|
License Name |
Standard enterprise for safety production |
|
Expire date |
2020-02-12 |
|
Issuing party |
Zhejiang Administration of Work Safety |
|
License Content |
Standardization level: 3 |
|
License No. |
ZJ20150167 |
|
License Name |
Good Supply Practice Certification |
|
Expire date |
2020-12-24 |
|
Issuing party |
Zhejiang Food and Drug Administration |
|
License Content |
APIs (Azithromycin and fudosteine) |
|
License No. |
ZJ20130125 |
|
License Name |
Good Supply Practice Certification |
|
Expire date |
2018-11-13 |
|
Issuing party |
Zhejiang Food and Drug Administration |
|
License Content |
APIs (Roxithromycin, Clarithromycin and Ciprofloxacin
hydrochloride) |
|
License No. |
(ZJ)WH AN XU ZHENG ZI (2015)-D-2260 |
|
License Name |
Administrative license for safety production |
|
Expire date |
2018-04-19 |
|
Issuing party |
Zhejiang Administration of Work Safety |
|
License Content |
Annual output: 2,000 tons of dichloromethane, 450 tons of
methanol, 620 tons of acetonitrile, 2,800 tons of ethyl acetate, 950 tons of
isopropanol, 2,100 tons of cyclohexane, 1,900 tons of acetone, 840m³/h of
compressed air and 200m³/h compressed nitrogen |
|
License No. |
(ZJ)WH AN XU ZHENG ZI
(2017)-D-0305 |
|
License Name |
Administrative license for safety production |
|
Expire date |
2020-06-18 |
|
Issuing party |
Zhejiang Administration of Work Safety |
|
License Content |
Annual output: 350m³/h of oxygen, 800m³/h of nitrogen; Annual filling: 1,000 tons of carbon dioxide, 1,000 tons
of argon, 1,000 tons of argon and carbon dioxide |
|
- |
File No. |
Punishment |
|
1 |
Yu Huan Fa Zi (2015) 12 |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. was fined CNY 241,302.00. |
|
2 |
Yu Huan Fa Zi (2016) 186 |
Abnormal use of water pollutants treatment facilities of
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. was registered and investigated on
2016-05-02. |
|
3 |
Yu Huan Fa Zi (2016) 13 |
- |
|
4 |
Yu An Jian Guan Fa Zi [2015] 22 |
Liabilities for explosion accident |
|
5 |
Yu Huan Fa Zi (2017) 10 |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. was fined CNY
80,000.00; |
|
File No. |
Yu Huan Fa Zi (2015) 12 |
|
Illegal Activities |
Abnormal use of water pollutants treatment facilities |
|
Punishment |
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. was fined CNY 241,302.00. |
|
Issuing Party |
Environmental Protection Bureau - Shangyu City |
|
Issuing Date |
2015-01-30 |
|
File No. |
Yu Huan Fa Zi (2016) 186 |
|
Illegal Activities |
Abnormal use of water pollutants treatment facilities |
|
Punishment |
Abnormal use of water pollutants treatment facilities of
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. was registered and investigated on
2016-05-02. |
|
Issuing Party |
Environmental Protection Bureau - Shangyu City |
|
Issuing Date |
2016-07-05 |
|
File No. |
Yu Huan Fa Zi (2016) 13 |
|
Illegal Activities |
Abnormal use of air pollutants treatment facilities |
|
Issuing Party |
Environmental Protection Bureau - Shangyu City |
|
Issuing Date |
2016-01-21 |
|
File No. |
Yu An Jian Guan Fa Zi [2015] 22 |
|
Illegal Activities |
Guobang Pharmaceutical "8•10" explosion accident
administrative penalty |
|
Punishment |
|
|
Issuing Party |
Zhejiang
Administration of Work Safety |
|
Issuing Date |
2015-12-30 |
|
File No. |
Yu
Huan Fa Zi (2017) 10 |
|
Illegal Activities |
Discharge
of foul gas |
|
Punishment |
ZHEJIANG
GUOBANG PHARMACEUTICAL CO., LTD. was fined CNY 80,000.00; |
|
Issuing Party |
Environmental
Protection Bureau - Shangyu City |
|
Issuing Date |
2017-02-14 |
|
Tax Payer |
ZHEJIANG
GUOBANG PHARMACEUTICAL CO., LTD. |
|
Authority / Information Source |
Shangyu
Municipal Office, SAT |
|
Value |
0 |
|
Date |
2011-09-20 |
TAX
ARREARS LIST
As of
the reporting date, no related record about subject is found through below
sources:
A.
Website of Tax Bureau of China;
B.
Website of local Tax Bureau of subject's location;
DEBT
ARREARS LIST
As of
the reporting date, no related record about subject is found through below
sources:
A.
Major telecommunication operators of China;
FINANCIAL INFORMATION
DETAILED FINANCIAL INFORMATION (UNIT: CNY 1,000)
Financial Note: Due to the lack of a clear government policy
regarding the transparency of enterprise financial information, some financial
items might be missing in the financial statements, causing possible inequality
between the sum of the provided items and the provided total numbers.
|
Assets |
|
|
|
Year |
2015-12-31 |
2016-12-31 |
|
Report Type |
Annual Report |
Annual Report |
|
Statement Type |
Individual |
Individual |
|
Source |
AIC |
AIC |
|
Audited or Not |
Unknown |
Unknown |
|
Total Assets |
1,498,590 |
1,662,902 |
|
Liabilities |
|
|
|
Year |
2015-12-31 |
2016-12-31 |
|
Total Liabilities |
803,933 |
797,491 |
|
Total Owner’s Equity |
694,657 |
865,411 |
|
Total Liabilities and Owner's
Equity |
1,498,590 |
1,662,902 |
|
Income Statement |
|
|
|
Year |
2015-12-31 |
2016-12-31 |
|
Operating Income |
1,387,612 |
1,454,788 |
|
Total Profit |
106,442 |
197,819 |
|
Income Tax |
15,997 |
29,673 |
|
Net Profit |
90,445 |
168,146 |
GROWTH
RATE OF MAJOR FINANCIAL
|
|
2015 |
Growth(%) |
2016 |
|
Operating Income |
1,387,612 |
4.84 |
1,454,788 |
|
Total Assets |
1,498,590 |
10.96 |
1,662,902 |
|
Total Profit |
106,442 |
85.85 |
197,819 |
|
Net Profit |
90,445 |
85.91 |
168,146 |
|
Total Liabilities |
803,933 |
-0.80 |
797,491 |
|
Total Owner’s Equity |
694,657 |
24.58 |
865,411 |
|
Profitability |
2015 |
2016 |
|
Return on net assets (%) |
13.02 |
19.43 |
|
Return on total assets (%) |
6.04 |
10.11 |
|
Net profit margin (%) |
6.52 |
11.56 |
|
Operation capacity |
2015 |
2016 |
|
Turnover of total assets |
0.93 |
0.87 |
|
Solvency |
2015 |
2016 |
|
Liabilities to assets ratio (%) |
53.65 |
47.96 |
|
Development capacity |
2015 |
2016 |
|
Yearly Growth of Operating Income (%) |
- |
4.84 |
|
Yearly growth of total assets (%) |
- |
10.96 |
FINANCIALS
& ANALYSIS
|
Financial Note |
Subject’s
detailed financial information of 2015 and 2016 is unavailable through all
available channels. Subject’s staff was contacted but declined to provide
relevant financial information. Hence only Subject’s financial summaries of
2015 and 2016 obtained from AIC source are provided for client’s reference. |
INDUSTRY INFORMATION
|
SIC (China) |
2710,Production of Original Medicine of Chemical Drugs 【Major】 |
|
ISIC |
2100,Manufacture of medicines, medical products and herbal
medicines |
|
NACE |
21.1,Manufacture of medicines, medical products and herbal
medicines |
INDUSTRY FINANCIAL AVERAGE
|
- |
2015 |
Subject |
Best(10%) |
Average |
Worst(10%) |
|
Solvency |
Liabilities to Assets Ratio (%) |
53.65 |
45 |
54 |
76.50 |
|
Current ratio |
- |
2.22 |
1.55 |
1.01 |
|
|
Quick ratio |
- |
1.39 |
0.96 |
0.63 |
|
|
Development Capacity |
Yearly Growth of Operating Income (%) |
- |
32.93 |
15.01 |
-7.11 |
|
Yearly Growth of Gross Profit (%) |
- |
26.77 |
6.61 |
-9.90 |
|
|
Yearly Growth of Total Assets (%) |
- |
28.22 |
11.54 |
-4.14 |
|
|
Profitability |
Return on net assets (%) |
13.02 |
24.30 |
11.87 |
-2.16 |
|
Return on total assets (%) |
6.04 |
14.45 |
8.62 |
-1.62 |
|
|
Gross profit margin (%) |
- |
50.51 |
35.39 |
14.67 |
|
|
Operation Capacity |
Turnover of total assets |
0.93 |
1.57 |
0.67 |
0.22 |
|
Turnover of current assets |
- |
2.91 |
1.79 |
1.01 |
|
|
Turnover days of account receivable |
- |
24.00 |
54.92 |
98.18 |
|
- |
2016 |
Subject |
Best(10%) |
Average |
Worst(10%) |
|
Solvency |
Liabilities to Assets Ratio (%) |
47.96 |
47.70 |
55.62 |
74.20 |
|
Current ratio |
- |
2.35 |
1.59 |
0.98 |
|
|
Quick ratio |
- |
1.47 |
0.99 |
0.61 |
|
|
Development Capacity |
Yearly Growth of Operating Income (%) |
4.84 |
34.90 |
15.46 |
-6.90 |
|
Yearly Growth of Gross Profit (%) |
- |
28.37 |
6.81 |
-9.60 |
|
|
Yearly Growth of Total Assets (%) |
10.96 |
29.92 |
11.88 |
-4.02 |
|
|
Profitability |
Return on net assets (%) |
19.43 |
25.76 |
12.23 |
-2.10 |
|
Return on total assets (%) |
10.11 |
15.31 |
8.88 |
-1.57 |
|
|
Gross profit margin (%) |
- |
53.54 |
36.45 |
14.23 |
|
|
Operation Capacity |
Turnover of total assets |
0.87 |
1.66 |
0.69 |
0.22 |
|
Turnover of current assets |
- |
3.09 |
1.85 |
0.98 |
|
|
Turnover days of account receivable |
- |
25.44 |
56.57 |
95.24 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 6738 |
|
|
1 |
INR 91.39 |
|
Euro |
1 |
INR 79.89 |
|
CNY |
1 |
INR 10.62 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
PRI |
|
|
|
|
Report Prepared
by : |
KET |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.